BUSINESS
    Takeda on Course to Stable Growth as Late-Stage Assets Near Market
    By Hayate Horiguchi May 9, 2025
    Takeda Pharmaceutical sees FY2025 as a pivotal year for the future growth of the company as it plans to tackle the final generic headwind of Vyvanse (lisdexamfetamine dimesylate) while preparing for the launch of late-stage…

    LATEST

    Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
    May 9, 2025
    Eli Lilly Japan registered double-digit growth for the second straight year in 2024, driven by a portfolio of new and growth products including the diabetes drug Mounjaro (tirzepatide) and migraine treatment Emgality (galcanezumab). “We have…
    Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
    May 9, 2025
    Ono Pharmaceutical saw its group profits tank more than 60% in FY2024 over the previous year as it booked costs related to the acquisition of Deciphera Pharmaceuticals, which drove up R&D spending and SGA expenses,…
    Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
    May 8, 2025
    The ruling Liberal Democratic Party (LDP) and Komeito and the opposition Japan Innovation Party (Nippon Ishin) met on May 7 for another round of discussions on social security reform, but they failed to work out…

    COMMENTARY

    New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
    By Hayate Horiguchi

    The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…

    COLUMN

    The Evolution of HR: From BP to Agile
    By Philip Carrigan

    The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo Debate on Off-Year Drug Price Revisions

    Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
    By Ken Yoshino

    Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

    TRENDS

    Top 10 PHARMA JAPAN Articles of 2024

    For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

    MHLW Panel on Generic Industry Structure

    MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report

    A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

    MHLW Panel on Pharmaceutical Regulations

    Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS

    The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA